Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

doi:10.3389/fonc.2020.575148

Review

. 2020 Nov 19:10:575148.

doi: 10.3389/fonc.2020.575148. eCollection 2020.

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Konstantinos Kamposioras¹, Davide Mauri², Konstantinos Papadimitriou³, Alan Anthoney⁴, Nadia Hindi^{5

6}, Branka Petricevic⁷, Mario Dambrosio⁸, Antonis Valachis⁹, Pantelis Kountourakis¹⁰, Jindrich Kopecky¹¹, Cvetka Grašič Kuhar¹², Lazar Popovic¹³, Nataliya P Chilingirova^{14

15}, George Zarkavelis², Ramon Andrade de Mello^{16

17}, Natalija Dedić Plavetić¹⁸, Christos Christopoulos¹⁹, Bianca Mostert²⁰, John R Goffin²¹, Dimitiros Tzachanis²², Haytham Hamed Saraireh²³, Fei Ma²⁴, Ida Pavese²⁵, Maria Tolia²⁶

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
² Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
³ Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium.
⁴ Leeds Institute of Medical Research at St James' Hospital, University of Leeds, Leeds, United Kingdom.
⁵ Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain.
⁶ TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla)/HUVR/CSIC/Universidad deSevilla), Sevilla, Spain.
⁷ Medizinische Abteilung, Zentrum für Onkologie und Hämatologie mit Ambulanz und alliativstation Wilhelminenspital, Vienna, Austria.
⁸ Department of Clinical Oncology, Clinica San Carlo, Milan, Italy.
⁹ Department of Oncology, Faculty of Medicine & Health, Örebro University, Örebro, Sweden.
¹⁰ Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
¹¹ Department of Clinical Oncology, University Hospital, Charles University-Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia.
¹² Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
¹³ Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
¹⁴ University Specialized Hospital for Active Treatment in Oncology, Medical Oncology Clinic, Sofia, Bulgaria.
¹⁵ Medical University Pleven, Pleven, Bulgaria.
¹⁶ Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil.
¹⁷ Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
¹⁸ University Hospital Centre, Zagreb Department of Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia.
¹⁹ Service de Radiothérapie Oncologique, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
²⁰ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
²¹ Department of Oncology, McMaster University Juravinski Cancer Centre, Hamilton, ON, Canada.
²² Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, United States.
²³ Radiation Oncology Department, Jordanian Royal Medical Services, Amman, Jordan.
²⁴ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
²⁵ Service d'Oncologie, GHT Grand Paris Nord-Est, Montfermeil, France.
²⁶ Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.

PMID: 33330049
PMCID: PMC7711151
DOI: 10.3389/fonc.2020.575148

Review

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Konstantinos Kamposioras et al. Front Oncol. 2020.

. 2020 Nov 19:10:575148.

doi: 10.3389/fonc.2020.575148. eCollection 2020.

Authors

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
² Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
³ Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium.
⁴ Leeds Institute of Medical Research at St James' Hospital, University of Leeds, Leeds, United Kingdom.
⁵ Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain.
⁶ TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla)/HUVR/CSIC/Universidad deSevilla), Sevilla, Spain.
⁷ Medizinische Abteilung, Zentrum für Onkologie und Hämatologie mit Ambulanz und alliativstation Wilhelminenspital, Vienna, Austria.
⁸ Department of Clinical Oncology, Clinica San Carlo, Milan, Italy.
⁹ Department of Oncology, Faculty of Medicine & Health, Örebro University, Örebro, Sweden.
¹⁰ Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
¹¹ Department of Clinical Oncology, University Hospital, Charles University-Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia.
¹² Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
¹³ Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
¹⁴ University Specialized Hospital for Active Treatment in Oncology, Medical Oncology Clinic, Sofia, Bulgaria.
¹⁵ Medical University Pleven, Pleven, Bulgaria.
¹⁶ Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil.
¹⁷ Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
¹⁸ University Hospital Centre, Zagreb Department of Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia.
¹⁹ Service de Radiothérapie Oncologique, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
²⁰ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
²¹ Department of Oncology, McMaster University Juravinski Cancer Centre, Hamilton, ON, Canada.
²² Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, United States.
²³ Radiation Oncology Department, Jordanian Royal Medical Services, Amman, Jordan.
²⁴ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
²⁵ Service d'Oncologie, GHT Grand Paris Nord-Est, Montfermeil, France.
²⁶ Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.

PMID: 33330049
PMCID: PMC7711151
DOI: 10.3389/fonc.2020.575148

Abstract

Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.

Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.

Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.

Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.

Keywords: Covid-19; international; oncology; recommendations; societies.

Copyright © 2020 Kamposioras, Mauri, Papadimitriou, Anthoney, Hindi, Petricevic, Dambrosio, Valachis, Kountourakis, Kopecky, Kuhar, Popovic, Chilingirova, Zarkavelis, de Mello, Plavetić, Christopoulos, Mostert, Goffin, Tzachanis, Saraireh, Ma, Pavese and Tolia.

PubMed Disclaimer

Cited by

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.
Janzic U, Bidovec-Stojkovic U, Mohorcic K, Mrak L, Dovnik NF, Ivanovic M, Ravnik M, Caks M, Skof E, Debeljak J, Korosec P, Rijavec M. Janzic U, et al. Future Oncol. 2022 Jul;18(23):2537-2550. doi: 10.2217/fon-2022-0148. Epub 2022 Jun 9. Future Oncol. 2022. PMID: 35678621 Free PMC article.
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic.
Napolitano S, Caputo V, Ventriglia A, Martini G, Della Corte CM, De Falco V, Ferretti S, Martinelli E, Morgillo F, Ciardiello D, De Vita F, Orditura M, Fasano M, Ciardiello F, Troiani T. Napolitano S, et al. Oncologist. 2022 Aug 5;27(8):e633-e641. doi: 10.1093/oncolo/oyac071. Oncologist. 2022. PMID: 35604409 Free PMC article.
Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer.
Kamposioras K, Lim KHJ, Williams J, Alani M, Barriuso J, Collins J, Marti K, Braun M, Mullamitha S, Hasan J, Alam N, Mahmood S, Finch S, Bayles L, King J, Saunders M. Kamposioras K, et al. Clin Colorectal Cancer. 2022 Jun;21(2):e117-e125. doi: 10.1016/j.clcc.2021.11.010. Epub 2021 Dec 1. Clin Colorectal Cancer. 2022. PMID: 34953674 Free PMC article.
COVID-19 Emotional and Mental Impact on Cancer Patients Receiving Radiotherapy: An Interpretation of Potential Explaining Descriptors.
Tolia M, Symvoulakis EK, Matalliotakis E, Kamekis A, Adamou M, Kountourakis P, Mauri D, Dakanalis A, Alexidis P, Varveris A, Antoniadis C, Matthaios D, Paraskeva M, Giaginis C, Kamposioras K. Tolia M, et al. Curr Oncol. 2023 Jan 1;30(1):586-597. doi: 10.3390/curroncol30010046. Curr Oncol. 2023. PMID: 36661695 Free PMC article.
Resilience in Rectal Cancer Treatment: Lessons from the COVID-19 Era in Czech Republic.
Ihnát P, Martínek L, Tulinský L, Kala Z, Grolich T, Gurlich R, Šturma J, Klos D, Špička P, Neoral Č, Černý V. Ihnát P, et al. Ther Clin Risk Manag. 2024 Jun 17;20:373-379. doi: 10.2147/TCRM.S455332. eCollection 2024. Ther Clin Risk Manag. 2024. PMID: 38912517 Free PMC article.

See all "Cited by" articles

References

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol (2020) 21(3):335–7. 10.1016/S1470-2045(20)30096-6 - DOI - PMC - PubMed
1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (2020) 395(10229):1054–62. 10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed
1. Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic ansd avoiding the distraction effect. Ann Oncol (2020) 31(5):553–5. 10.1016/j.annonc.2020.03.286 - DOI - PMC - PubMed
1. Chen YC, Huang LM, Chan CC, Su CP, Chang SC, Chang YY, et al. SARS in hospital emergency room. Emerg Infect Dis (2004) 10(5):782–8. 10.3201/eid1005.030579 - DOI - PMC - PubMed
1. Infection Prevention and Control of Epidemic- and Pandemic-Prone Acute Respiratory Infections in Health Care. Geneva: World Health Organization; (2014). Available at: https://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_en... (Accessed on 30 April, 2020). - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol (2020) 21(3):335–7. 10.1016/S1470-2045(20)30096-6 - DOI - PMC - PubMed

[2] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol (2020) 21(3):335–7. 10.1016/S1470-2045(20)30096-6 - DOI - PMC - PubMed

[3] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (2020) 395(10229):1054–62. 10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed

[4] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (2020) 395(10229):1054–62. 10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed

[5] Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic ansd avoiding the distraction effect. Ann Oncol (2020) 31(5):553–5. 10.1016/j.annonc.2020.03.286 - DOI - PMC - PubMed

[6] Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic ansd avoiding the distraction effect. Ann Oncol (2020) 31(5):553–5. 10.1016/j.annonc.2020.03.286 - DOI - PMC - PubMed

[7] Chen YC, Huang LM, Chan CC, Su CP, Chang SC, Chang YY, et al. SARS in hospital emergency room. Emerg Infect Dis (2004) 10(5):782–8. 10.3201/eid1005.030579 - DOI - PMC - PubMed

[8] Chen YC, Huang LM, Chan CC, Su CP, Chang SC, Chang YY, et al. SARS in hospital emergency room. Emerg Infect Dis (2004) 10(5):782–8. 10.3201/eid1005.030579 - DOI - PMC - PubMed

[9] Infection Prevention and Control of Epidemic- and Pandemic-Prone Acute Respiratory Infections in Health Care. Geneva: World Health Organization; (2014). Available at: https://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_en... (Accessed on 30 April, 2020). - PubMed

[10] Infection Prevention and Control of Epidemic- and Pandemic-Prone Acute Respiratory Infections in Health Care. Geneva: World Health Organization; (2014). Available at: https://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_en... (Accessed on 30 April, 2020). - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Affiliations

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources